BernardGRVincentJLLaterrePF. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med2001;344: 699–709.
3.
AbrahamELaterrePFGargR. Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med2005;353: 1332–41.
4.
FinferSRanieriVMThompsonBT. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med2008;34: 1935–47.
5.
RiceTWWheelerAPBernardGR. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med2010;38: 1685–94.
6.
TidswellMTillisWLaRosaSP. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med2010;38: 72–83.
7.
LevyMMDellingerRPTownsendSR. The Surviving Sepsis Campaign: results of an international guideline based performance improvement program targeting severe sepsis. Crit Care Med2010;38: 367–74.
8.
HarrisonDAWelchCAEddlestonJM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care2006;10: R42.
9.
KublerAMayzner-ZawadzkaEDurekG. Results of severe sepsis treatment program using recombinant human activated protein C in Poland. Med Sci Monit2006;12: CR107–112.
10.
DhainautJ-FPayetSValletB. for the PREMISS Study Group. Cost-effectiveness of activated protein C in real-life clinical practice (PREMISS). Crit Care2007;11: R99.
11.
BertoliniGRossiCAnghileriA. Use of drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med2007;33: 426–434.
12.
KanjiSPerreaultMMChantC. Evaluating the use of drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med2007;33: 517–23.
13.
RidleySLwinAWyncollD. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice. Eur J Anaesthesiol2008;25: 211–16.
14.
WheelerASteingrubJSchmidtGA. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial. Crit Care Med2008;36: 14–23.
15.
RowanKWelchCNorthEHarrisonD. Drotrecogin alfa (activated): real-life use and outcomes for the UK. Crit Care2008;12: R58.
16.
VincentJLLaterrePFDecruyenaereJ. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units – an observational study. Acta Clin Belg2008;63: 25–30.
17.
MartinGBrunkhorstFMJanesJM. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care2009;13: R103.
18.
FerrerRArtigasASuarezD. Effectiveness of treatments for severe sepsis: a prospective multicenter observational study. Am J Respir Crit Care Med2009;180: 861–66.
19.
LindenauerPKRothbergMBNathansonBH. Activated protein C and hospital mortality in septic shock: A propensity-matched analysis. Crit Care Med2010;38: 1101–07.
20.
SteingrubJSCheathamMLWoodwardB. A prospective, observational study of Xigris Use in the United States (XEUS). J Crit Care2010;25: 660. e9–16.
21.
BoyleAMcKensieCMcLuckieA. Adverse events and clinical outcome associated with drotrecogin alfa-activated: A single-center experience of 498 patients over 8 years. J Crit Care2011 (in press). Published online on 15 December 2011.
